首页> 外国专利> HUMAN TRANSFORMED CHONDROCYTE CELL LINE-BASED DRUG SCREENING SYSTEM FOR CARTILAGE DISEASES

HUMAN TRANSFORMED CHONDROCYTE CELL LINE-BASED DRUG SCREENING SYSTEM FOR CARTILAGE DISEASES

机译:基于人转化软骨细胞的药物筛查系统

摘要

The present invention relates to a recombinant expression vector for cartilage disease drug screening, a cell line transformed by the expression vector, and a method for screening a drug effective in treating cartilage diseases by using the same, wherein since all the components forming the expression vector are human-derived genetic factors, novel drugs screened thereby are deemed to be more effective in the treatment of cartilage diseases in human. Further, since the present invention enables to determine whether or not cartilage diseases of a gene of an unknown function are treatable, through additional transformations, the present invention enables comparisons of various drugs in terms of a cartilage disease treatment function, and is also expected to enable evaluations on optimal treatment concentrations and indirect cytotoxicity. Finally, a novel substance having cartilage regeneration efficacy discovered through a screening system according to the present invention, 2-anthraquinonecarboxylic acid, is promising to be applicable to the treatment of various cartilage diseases.;COPYRIGHT KIPO 2020
机译:本发明涉及用于软骨疾病药物筛选的重组表达载体,由该表达载体转化的细胞系以及通过使用该载体筛选有效治疗软骨疾病的药物的方法,其中由于构成表达载体的所有成分由于是人类衍生的遗传因素,因此筛选出的新药被认为在治疗人类软骨疾病方面更为有效。此外,由于本发明使得能够确定功能未知的软骨疾病是否可治疗,因此通过额外的转化,本发明使得能够就软骨疾病的治疗功能对各种药物进行比较,并且有望实现可以评估最佳治疗浓度和间接细胞毒性。最后,通过本发明的筛选系统发现的具有软骨再生功效的新物质2-蒽醌羧酸有望用于治疗各种软骨疾病。COPYRIGHTKIPO 2020

著录项

  • 公开/公告号KR102084227B1

    专利类型

  • 公开/公告日2020-03-03

    原文格式PDF

  • 申请/专利权人 LUGEN SCI;

    申请/专利号KR20190105987

  • 发明设计人 LEE JONG MIN;

    申请日2019-08-28

  • 分类号C12N15/86;C12N5/077;G01N33/50;

  • 国家 KR

  • 入库时间 2022-08-21 11:05:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号